Home / Journals International Journal of Pharmacy and Chemistry / Analysis and Removal of Genotoxic Impurities in Pharmaceutical Compounds
Analysis and Removal of Genotoxic Impurities in Pharmaceutical Compounds
Submission Deadline: May 30, 2017

This special issue currently is open for paper submission and guest editor application.

Join as Guest Editor Submit to Special Issue
Lead Guest Editor
Göksel Arli
Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey
Guest Editors
  • Murat Soyseven
    Department of Medical Services and Techniques/Yunus Emre Vocational School, Anadolu University, Eskişehir, Turkey
  • Rüstem Keçili
    Department of Medical Services and Techniques/Yunus Emre Vocational School, Anadolu University, Eskişehir, Turkey
Guidelines for Submission
Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.
Papers should be formatted according to the guidelines for authors (see: http://www.sciencepublishinggroup.com/journal/guideforauthors?journalid=330). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.
Published Papers
The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.
Introduction
The presence of chemicals also called impurities in pharmaceutical compounds may effect the efficiency and reliability of the final product. Especially, trace amount of genotoxic impurities in the pharmaceutical compounds play a crucial role in human mutagenicity and carcinogenicity. Considering this matter, either pharma industry or regulatory authorities have carefully focused on this issue. In 2007, a genotoxic compound ethyl mesylate was determined in some batches of Viracept which is an antiviral drug used for the treatment of AIDS produced by Roche. Thereupon, EU has suspended the licence of the drug and drug has been recalled. After this incident, research on the determination and removal of genotoxic impurities has rapidly increased.
This special issue aims to provide a comprehensive collection of original research articles on the analysis and removal of genotoxic impurities in pharmaceutical compounds.

Aims and Scope:
Development of analytical methods for the analysis of genotoxic impurities
Design and preparation of new materials for the removal of genotoxic impurities
Purification of pharmaceutical compounds
Application of polymers in genotoxic impurity removal
Application of reactive scavengers in genotoxic impurity removal
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186